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Abstract: Despite being a biological waste, human urine contains a small population of cells with
self-renewal capacity and differentiation potential into several cell types. Being derived from the
convoluted tubules of nephron, renal pelvis, ureters, bladder and urethra, urine-derived stem cells
(UDSC) have a similar phenotype to mesenchymal stroma cells (MSC) and can be reprogrammed
into iPSC (induced pluripotent stem cells). Having simple, safer, low-cost and noninvasive collection
procedures, the interest in UDSC has been growing in the last decade. With great potential in
regenerative medicine applications, UDSC can also be used as biological models for pharmacology
and toxicology tests. This review describes UDSC biological characteristics and differentiation
potential and their possible use, including the potential of UDSC-derived iPSC to be used in drug
discovery and toxicology, as well as in regenerative medicine. Being a new cellular platform
amenable to noninvasive collection for disease stratification and personalized therapy could be a
future application for UDSC.
Keywords: urine-derived stem cells; personalized medicine; regenerative medicine; induced-pluripotent
stem cells
1. Morphological Characterization and Early Applications of Urine-Derived Stem Cells
Whenever a tissue is under constant stress from various factors (physical, chemical or mechanical),
increased cell proliferation, high regeneration rate of the tissue and presence of regional stem cells
is often observed. The fast renewal capability of skin and mucous layer of the stomach is one such
example. In this context, urine also contains toxic metabolic wastes, having high osmotic pressure and
a nonphysiological pH [1], which converts it into an aggressive body fluid that dramatically changes
with the type of insult. These characteristics justify why the urinary tract, as an excretory organ, reveals
a high regeneration potential as well. Due to this, the search for regional tissue-specific stem cells of
the urinary system gained momentum in the last decade.
The first cells from the urinary tract that were isolated, cultivated and characterized in vitro were
exfoliated urinary cells from newborn children, initially described in 1972 by Sutherland and Bain [2].
Four years later, Linder described the culture of cells from the urine and bladder washings of adults [3].
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Several follow-up papers reported the isolation, culture and growth properties of human urinary
epithelial cells (urothelial cells) [4–6]. Independently, Herz et al. described the culture of urinary cells
from adults [7,8].
The optimization of the culture conditions for epithelial cells from newborn urine, namely on
plates covered by collagen-I matrix in serum-free medium consisting of a 1:1 mixture of Dulbecco’s
modified Eagles’ medium (DMEM) and Ham’s F-12 medium supplemented with insulin, transferrin,
selenium and hydrocortisone was described [9]. Under these conditions, epithelial cells were able to
undergo five passages while retaining the original morphology. Another alternative methodology for
epithelial cells isolation from four to six-week-old rat urinary bladders was suggested by Johnson et al.
by performing an attachment of bladder mucosal explants to collagen-I gels and the addition of the
epidermal growth factor (EGF) [10]. The cultured cells had similar characteristics to human urothelial
cells, namely junctional complexes, desmosomes, stratification and apical glycocalyx, while the ability
of derived cells to be serially passaged increased 100-fold. Since bladder urothelial cells are in contact
with interstitial cells, Howlett et al. described the culture of isolated urothelial cells on the feeder layer
of embryonic mesenchymal-derived (Swiss 3T3) cells and collagen-I matrices [11]. Using this protocol,
the culture of urothelial cells using conditioned medium from 3T3 cells was not enough to support
the expression of tissue-specific characteristics. This indicated that direct intercellular contacts are
necessary. Moreover, such culture models simplified three-dimensional tissue-like facsimiles of bladder
stroma [11]. Another important factor determining viability, growth kinetics and cell differentiation is
the cell culture medium and its supplements [12]. Variations in calcium concentration may affect cell
growth capabilities, since with high calcium concentrations viability of growing cultures decreases,
suggesting an accelerated rate of cellular differentiation. On the other hand, cells fail to form stratified
epithelium in low-calcium medium [12,13]. For maintenance of the stratified structure of urothelial
cells in long-term cultivation, it is preferred to cultivate cells in collagen-covered flasks [14], although
more effective results were achieved by cultivating cells on a porous collagen matrix in cell medium
supplemented with fetal bovine serum (FBS), hormones and calcium [13,15].
Urothelial cells can be isolated not only by urine sedimentation, as previously performed, but also
by biopsies from renal pelvis, ureter, bladder and urethra [16]. This method is effective, allowing the
isolation of cells from distinct tissues and in larger quantities, in comparison with those obtained by
using a sedimentation technique. Nonetheless, biopsy is an invasive procedure which can present
different complications, during and after the manipulation, and should be avoided whenever possible.
An alternative method to obtain stratified urothelial cell layers was described by
Gustafson et al. [17], involving the cultivation of urothelial cells on decellularized skin grafts.
The advantage of this approach is its short time of cultivation, facilitation of transplantation procedure,
opportunity to transplant undifferentiated cells and formation of a vascular network under a urothelium
graft. As the authors suggested, this method provides autologous urothelium for reconstructive
surgery in the genitourinary tract [17].
Immunomagnetic beads, conjugated with monoclonal antibodies to aminopeptidase M (APM,
CD13) allowed to isolate proximal tubule cells and an addition of antibodies to Tamm-Horsfall
glycoprotein, a specific antigen for the thick ascending limb, and the early distal convoluted tubule
allowed the separation of distal tubular cells [18].
Isolation and cultivation of two other different cell types from human urine sediments were
performed by Dörrenhaus et al. [19]. In this work, authors described two cell populations: (a) type 1
cells presented irregular contours, including spindle-like cells inside colonies, expressed cytokeratin-7
(marker of urothelial cells), were cultivated up to six passages and formed cobblestone-like cells and
domes (hemicysts); (b) type 2 cells had smooth-edged contours, stained positively with carbonic
anhydrase (marker of renal tubular epithelium) and subcultivation was not possible. According to
the results, type 1 cells were thought to be a urothelial population, originated within the urinary
tract, while type 2 were considered renal tubular cells [19]. Figure 1 summarizes potential sources,
morphological and phenotypic characterizations of different types of urine-derived cells.
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Figure 1. Potential sources, morphological and phenotypic characterizations of different types of
urine-derived stem cells. Upper urinary tract cells can be derived from renal cortical nephron part–renal
tubular cells from proximal and distal convoluted tubules [19,20], glomerular pericytes [21,22], renal
interstitial cells [21,23,24] and vascular endothelial cells [21,25]. Lower urinary tract urine-derived stem
cells (UDSC) belong to epithelial (urothelial) cells from ureter, urinary bladder and urethra [19,21,26].
Original source of UDSC determines their morphology in vitro, culture conditions, phenotype and
differentiation capabilities. Image was adapted from original images from Servier Medical Art,
as licensed under a Creative Commons Attribution 3.0 Unported License. Text was added to the
original images.
An alternative method for the isolation and long-term cultivation of differentiated rat urothelial
cells was introduced by Zhang et al. [26]. Cells were isolated by enzymatic digestion of the urothelium
and then cultivated during a period of four to five months, subcultured up to 18 passages and stained
positively with antibody to cytokeratin 17 (marker of epithelial phenotype), forming stratified urothelial
sheets similar to the native tissue. Following these results, Zhang and Frey discussed the use of this
technique to obtain autologous grafts for bladder surgical augmentation [27]. In this surgical context,
part of stomach or bowel is normally used, but since their mucosa is not specialized for a persistent
contact with urine, gastrocystoplasty or entero-cystoplasty were accompanied by several complications.
Since graft demucosalization usually led to its fibrosis and shrinkage, Zhang and Frey offered an
original solution to the problem by using de-epithelialized bowel lined with autologous urothelium,
achieving decreased graft shrinkage in experimental cystoplasty [27].
Another method for bladder urothelial cells isolation involves bladder lavage [28], first described
by Linder [3]. The authors demonstrated that isolated cells needed feeder cells in order to establish
primary cultures. If further cultured without the same feeder cell layer, high quality urothelial
cells would then be obtained with a normal karyotype during 14 passages, while maintaining
proliferation capacity after cryopreservation [28]. Despite their ability to grow in vitro, form colonies
and proliferate, these urothelial cells are not considered stem cells. Although a great potential in the
treatment of genitourinary tract diseases, they can only restore the mucous epithelium and do not have
multi-differentiation potential, one of three criteria, together with clonogenicity and self-renewal, that
characterize stem cells [21].
Stem-like cells were also described in the urinary system. Zhang et al. [21] described four different
cell populations, including stem cells, isolated from voided urine, and their characteristics studied.
Following this first work, other groups reproduced this experiment, and the existence of urine-derived
stem cells (UDSC) was gradually accepted by other researchers [29,30]. Since UDSC can be obtained
by noninvasive procedures, their isolation and cultivation are easy and inexpensive [21]; urine is now
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considered a promising source of stem cells, and several follow-up studies have been performed in
recent years with refined approaches.
Conditions of urine collection and storage that may affect the quality and quantity of UDSC have
been studied. It was previously demonstrated that UDSC from 13- to 40-year-old humans have the
highest rate of clonogenicity and, in order to obtain a large number of cells, catheterization, triple urine
samples collection [21] or upper urinary tract urine collection [20] are recommended. Collection of
urine from the upper urinary tract is an alternative solution for patients with bladder cancer, if the renal
pelvis and upper part of the ureter are not affected [25]. Isolation of UDSC from fresh urine is preferable,
but protocols for UDSC isolation can be performed within 24 h if urine is stored at 4 ◦C in a storage
medium with serum; longer storage negatively influences the viability of cells [30]. Recommendation
on the process of urine collection, including exclusion criteria (e.g., viral or bacterial infections and
malignancies) for future regenerative medicine, have been previously published; nevertheless, the
future will bring advances in the automatic recovery of cells from the urine and possibly rescuing
UDSC from otherwise excluded individuals [31].
Subsequently to urine cell pellet seeding, cells tend to grow in colonies. Once cells achieve
confluence, they should be subcultured. The average population doubling time varies between 20 and
29 h for fresh urine and between 28 to 32 h for urine preserved at 4 ◦C during 24 h [20,30]. Studies
about urine preservation for UDSC isolation are still scarce [30], and it is an important point to be
addressed, since it would bring several advantages to the process of UDSC isolation. Although values
can vary according to culture conditions, Bharadwaj et al. achieved an average of 3.7 × 108 UDSC
cells, at passage 5, in about 27 days of culture [20]. UDSC can be isolated from individuals from both
genders and with an age range reported so far from 5 to 75 years [32]. In adult cells, telomerase activity
is largely limited to stem cells and is associated with a high proliferative capacity. Bharadwaj et. al.
described telomerase activity in 60% of independent UDSC samples [32], while a normal karyotype
was found at least until cell passage 15 [20,21,29,30]. The Supplementary Materials contains culture
conditions, biological characteristics and differentiation of UDSC.
After UDSC isolation, questions about their phenotype, origin and differentiation potential arise.
A common method to identify and characterize a stem cell phenotype is based on the analysis of cell
surface markers known as clusters of differentiation (CD). For UDSC, the CD phenotype is similar to
MSC, expressing CD73, CD90, CD105 and CD133, while CD markers of HSC (CD45, CD31 and CD34)
are not present [21,25,32]. Besides distinct CD markers, the exact origin of UDSC can be studied through
the detection of other specific markers for various cell populations of the urinary system. Detailed
comparisons of the phenotype of UDSC with renal tubular cells, urothelial, endothelial, interstitial
and other types of cells was already published by Manaph et al. [22]. Although most UDSC markers
are similar to that of MSC, the former cells also express other markers of pluripotent cells, including
POU5F1 or octamer-binding transcription factor 3/4 (Oct 3/4), a VMyc avian myelocytomatosis viral
oncogene homologue (c-Myc), as well as renal markers, such as sine oculis homeobox homologue 2
(SIX2) or the neural cell adhesion molecule (NCAM) [22]. As suggested by Manaph et al., UDSCs
should also be considered as renal progenitor cells due to the above-mentioned markers, in addition
to other markers present. In other words, UDSC can be a source of MSC-like cells, which present
some but not all markers typical of the latter cells, although presenting high expandability and high
proliferative ability typical from other stem cells [33].
Despite this, the origin of UDSC remains controversial [20]. According to some authors, collected
UDSC originate from the kidneys, because cells obtained from female patients who received a
sex-mismatched kidney transplant contained the Y-chromosome and expressed normal kidney cell
genes and protein markers common for parietal cells and podocytes from the upper urinary tract (renal
pelvic and/or upper segments of transplanted ureter) [20]. Other authors suggested instead that UDSC
originates from the basal layer of urothelium [34], pericytes of kidney [35] or urinary epithelium [25].
Such possible diversity of origins may result in the presence of various cell populations in the urine.
Zhang et al. [21,26,27] described four distinct types of cells, with each one presenting distinct origins: (a)
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cobblestone-like cells, expressing uroplakin-Ia from urothelial origin; (b) spindle-shaped desmin+cells
from muscle origin; (c) cells with circular morphology and expression of vWF (von Willebrand’s factor)
from endothelial origin and (d) elongated and expressing c-kit cells, considered as interstitial cells.
The number of cells and their origin is also determined by the procedure used for urine
collection—more cells may be present in urine collected by using a urethral catheter due to
catheter-induced injury of the bladder and urethral mucosa [30]. Most of the cells are basically
quiescent until injury, and according to clinical and scientific viewpoints, cells from hematological (such
as erythrocytes) and epithelial origin (renal tubular cells, transitional epithelial cells and squamous
epithelial cells) can be found in urine, normally in low amounts [31].
Related with the immune system, another important marker that distinguishes UDSC from
hematopoietic stem cells is class II HLA (human leucocytes antigen) glycoproteins, which are common
for antigen-presenting cells (dendritic cells, macrophages, B-lymphocytes and some activated cells).
According to numerous independent studies, human UDSC do not express HLA-DR (one of class
II HLA glycoproteins) responsible for the triggering of an immune reaction [36–40]. Furthermore,
this immunogenic HLA-DR glycoprotein does not appear during in vitro UDSC culture until passage
7, so absence of this marker is considered as the reason for the immune suppressive effect of USCs
transplantations [40]. This fact highlights the fact that UDSC are an attractive cell source for therapeutic
application. At the same time, there is no clear information about the expression levels of class I HLA
markers, glycoproteins present in the cell membrane of almost all nucleus-containing cells, which
restricts opportunities of allogenic transplantation. We would then agree with Gaignerie et al. when
stating that the transplantation of UDSC should be addressed according to the specific HLA haplotypes
of the donor [41]. It also needs to be stressed that implantation of UDSC does not lead to teratoma
formation [21,25,32].
UDSC can differentiate into various cell lineages of the urinary system—cells with urothelial,
smooth muscle, endothelial and interstitial markers expression [21,29,42], as well as in mesenchymal
derivatives: osteoblasts, chondrocytes and adipocytes [42]. Under specific conditions in terms of
culture induction media, Bhadawaraj et al. obtained cells from the three germ layers—ectoderm
(neuronal differentiation); mesodermal (smooth muscle cells, as well as osteogenic, chondrogenic,
adipogenic, myogenic and endothelial differentiation) and endoderm (urothelial cells) [32,43]. In vitro
differentiation into smooth muscle-like cells was also performed by Bhadawaraj et al., who cultivated
UDSC in a differentiation medium. UDSC acquired not only the phenotype but also demonstrated
a contractile function similar to native smooth muscle cells [20]. Wu et al. recently showed that
UDSC had better adipogenic and endothelial capacities, as well as the potential to originate new
vascularization, when compared to bone marrow-derived stem cells [36].
Urothelial-differentiated UDSC express urothelial-specific genes and proteins, such as uroplakin-Ia
and -III, cytokeratin (CK)-7 and CK-13. Renal differentiation of UDSC can be performed by cultivating
cells in commercial kidney differentiation medium [42]. Importantly, and as described above,
transplanted UDSC do not lead to teratoma formation [20] or kidney abnormalities [42].
Urothelial differentiation of UDSC can be induced by implantation of UDSC into bacterial cellulose.
As a result, the formation of a multilayered urothelium that can be used as a urinary conduit for
urological operations was reported [34]. Following this study, UDSC were first differentiated in vitro
into urothelial cells and smooth muscle cells, seeded afterwards on 3D-porous small intestine submucosa
scaffolds and transplanted into athymic mice. Later, the authors demonstrated the formation of tissue,
similarly to native ureter [44]. To improve vascularization of the graft, human UDSC were infected with
an adenoviral vector containing the mouse vascular endothelial growth factor (VEGF) gene, co-cultured
with human umbilical vein endothelial cells in a collagen-I gel and implanted subcutaneously into
athymic mice. As a result, the authors observed increased in vivo survival and myogenic differentiation
of a UDSC graft. Besides increased vascularization, new nerve fibers were observed at 28 days of the
experiment [44].
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The potential of UDSC for therapeutic application in urologic operations was also shown by
Bhadawaraj et al. [32]. Similarly, to the work by Wu et al., UDSC were differentiated into urothelial and
smooth muscle cells in vitro and then seeded on small intestinal submucosa scaffolds, cultivated for 14
days and implanted into nude mice. Multilayered tissue-like structures were observed consisting of
urothelium and smooth muscle, proving that UDSC could be a source of cells for tissue-engineered
therapeutic strategies for patients with chronic bladder diseases or for those from whom adequate
cells cannot be obtained by biopsy [32]. In another context, intravenous injection of UDSC for
protamine/lipopolysaccharide-induced interstitial cystitis in rats led to inhibition of oxidative stress,
inflammatory response and cellular apoptosis, thus providing improvement of bladder function in
experimental interstitial cystitis [45].
Neurogenic differentiation of UDSC was demonstrated in vitro in several works [29,32]. Besides
in vitro studies, Guan et al. investigated whether UDSC could serve as a potential cell source for neural
tissue engineering in vivo and compared UDSC with adipose tissue-derived MSC (ADSC). When
seeding UDSC on a hydrogel scaffold and transplanting them into rat brains, UDSC behaved similarly
to ADSC. Cells survived in the lesion site and migrated to other brain areas, expressing neurogenic
markers such as glial fibrillary acidic protein, β-III tubulin and nestin. The observations show that
UDSC can differentiate into neuron-like cells in the rat brain and demonstrate promising potential for
regenerative medicine [29].
Being easily harvested without using invasive procedures and having the capacity to differentiate
into osteoblasts prompted the interest of UDSC in bone tissue engineering. Guan et al. demonstrated
that USCs were able to adhere, survive, proliferate and differentiate into osteoblasts in beta-tricalcium
phosphate (β-TCP), a typical scaffold used in bone tissue engineering [38]. The authors also further
demonstrated that the combination of UDSC andβ-TCP improved bone regeneration in rats, suggesting
UDSC as an alternative source of stem cells for bone tissue engineering. A study from Gao et al.
demonstrated that the age of urine donors influences the proliferation rates, senescence tendency and
osteogenic differentiation capacity of UDSC [46]. According to the authors, UDSCs from younger donors
are better models for basic research and may have more extensive clinical applications. Nevertheless,
the authors suggested that, independently from age, UDSC have potential applications in bone tissue
engineering as seed cells.
The range of UDSC differentiation capabilities made those cells a promising source of stem cells
for the treatment of various diseases. An antifibrotic effect and inhibition of cellular apoptosis was
demonstrated in experimental streptozocin-induced type 2 diabetes rats. Transplantation of UDSC
inhibited cell apoptosis, contributing to reduced fibrosis development and improving pancreas, heart,
kidney and bladder functions [43].
Compared to other MSC sources, collection of voided urine is noninvasive, thus painless, and
safe for patients, which is particularly important for pediatric patients. Although UDSC are actively
studied, their clinical application has not yet been appropriately tackled, although autologous urothelial
cells, cultivated in vitro on acellular allogenic dermis, were already successfully used for the surgical
treatment of hypospadias [47].
Advantages of UDSC isolation made them an attractive source of induced pluripotent stem cells,
initially generated by Zhou et al. [48]. Induced pluripotent stem cells (iPSC) can be applied to model
various human diseases “in vitro” and have already been established in different diseases: cardiac [49],
endocrine [50], neural [51], muscular [52], aneuploidy diseases such as Down syndrome [53] and
systemic lupus erythematousus [54], among others.
UDSC may be applied, not only for regenerative medicine but may also be used for the diagnosis
of genetic disorders, allowing to store samples of patients with inherited diseases. Since UDSC isolation
from patients with spinal muscular atrophy, Duchenne muscular dystrophy, paroxysmal kinesigenic
dyskinesia and Wilson’s disease were already successfully established, it is possible to obtain cell
samples from those individuals in a noninvasive and simple manner and use those cells for detecting
genetic alterations [55].
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2. Generation of iPSC from Urine-Derived Stem Cells (UDSC)
In 2006, Takahashi and Yamanaka showed that adult fibroblasts can be reprogrammed by the
addition of four transcription factors: Oct3/4, Sox2, c-Myc and Klf4, to generate iPSC, which behave as
embryonic stem cells in terms of unlimited self-renewal capacity and ability to virtually give rise to all
types of cells of the organism, excluding extra-embryonic tissues [56]. Furthermore, iPSC circumvents
ethical issues and immune rejection of embryonic stem cells. iPCS are a very effective tool for research,
preserving the characteristics of the original cell, such as genetic mutations and epigenetic alterations,
with potential applications in personalized regenerative medicine, in vitro pharmacological tests and as
disease model [57]. Commonly, the differentiation of iPSC into disease-relevant cell types is imperative,
since the disease phenotype is often only shown in differentiated cells. It was already demonstrated
that these differentiated cells have disease characteristics. As a summary of the several possible
fields of iPSC applications, the following can be mentioned: (a) iPSC technologies allow to generate
patient-specific iPSC lines and differentiate them in multiple necessary lineages; (b) as a cell model to
study the pathophysiology of diseases; (c) as disease models to develop and test new therapeutic drugs
and strategies, including cell-target specific treatment; (d) to study genetic and epigenetic abnormalities,
splicing and post translational modifications; (e) to study gene-editing technologies for the treatment
of genetically inherited diseases and (f) to use differentiated iPSC for cell and organ transplantations in
the clinic. The ability to generate iPSC from autologous cells reduces ethical problems and the risk for
immunological rejection (Figure 2).
Figure 2. Possible applications for urine-derived cells. After urine collection from healthy or
disease-affected individuals, urine-derived cells are cultured and reprogrammed into induced
pluripotent stem cells (iPSC). Those cells can be differentiated into condition-relevant cell types
maintaining the original genome. Otherwise, the genome can be edited to correct mutations or to
introduce alterations associated with disease treatments or for research purposes. These differentiated
cells can be used for autologous or allogeneic regenerative medicine as a model to study diseases or for
pharmacological tests, both in personalized or high-throughput approaches.
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Several human cell types, such as fibroblasts, bone marrow mesenchymal stroma cells, peripheral
blood, keratinocytes, melanocytes, dental pulp stem cells, hepatocytes, amniotic fluid-derived cells,
neural stem cells, cord blood stem cells and adipose stem cells, have been reprogrammed to iPSC [58].
UDSC are an alternative source of cells for iPSC generation, with the advantage of being collected by a
noninvasive method [53,54,59]. Several protocols have been studied to efficiently and safely generate
pluripotent stem cells, including nonintegrative approaches, without the requirement of feeders, serum
and the oncogene c-MYC—for example, using the combination of the transcription factors OCT4,
SOX2, SV40T, KLF4 and the miR-302-367 cluster or Oct4, Glis1, Klf4, Sox2, L-Myc and the miR-302
cluster, combined with a short incubation with four compounds (inhibitors of lysine-demethylase1,
methyl ethyl ketone, glycogen synthase kinase 3 beta and histone deacetylase) [57,60]. Moreover,
UDSC appear to be easier for the induction of a pluripotent state than skin fibroblasts, possibly because
urinary cells do not require the mesenchymal-to-epithelial transition (MET). This idea is supported by
the MET inductive expression profile found in urinary cells [57]. It would be interesting to evaluate
whether some specific characteristics of a UDSC subpopulation—for example, regarding surface
markers—influence the efficiency of iPSC generation and properties of themselves and cells obtained
by differentiation. There is still a lack of work about the properties of both urine-derived iPSC and
mature cells generated from them, obtained from healthy or unhealthy individuals.
3. Urine-Derived Stem Cells (UDSC) in Drug Discovery Therapeutics and Toxicology
In silico, in vitro and in vivo approaches have been used in human predictive toxicology. However,
due to the increasing production of new molecules with potential human applications, the currently
available approaches do not respond quickly and effectively to the requirements of the industry.
Human cells, with the advantages of recapitulating the precise physiologic signaling mechanisms, can
be used in a personalized way and for high-throughput screenings. The unmet need for new toxicology
models has been recognized by a committee from the U.S. National Academy of Sciences, which
urged the need for more efficient and relevant methods to assess human risks of exposure to different
chemicals and pharmaceuticals [61,62]. Improvement in models, including human-derived stem cells,
3D organotypic culture models, mathematical modeling of cellular processes and morphogenesis,
represents a clear movement towards in vitro/in silico-based assessments [62]. In vivo studies are
also frequently used in predictive toxicology, but due to ethical issues, the use of animals in scientific
research has been restricted, highlighting the need for alternative approaches and new models. With
a noninvasive, low-cost collection, simple isolation methods, efficient proliferation and multipotent
differentiation potential, UDSC are an important discovery in cell therapy and tissue engineering, with
possible applications in regenerative and personalized medicine [31,39,63]. Clonogenicity, self-renewal
capacities, the ability to reprogram to iPSCs [57,64] and the ability to differentiate in vitro into several
lineages make USDC potential biological models for in vitro predictive toxicological tests with higher
human relevance. In fact, Guan and co-workers [64] observed that UDSC reprogram to iPSCs easier
and quicker than fibroblasts or MSCs and maintain the original genetic characteristics. The authors
also highlighted UDSC as a novel biological resource for personalized medicine and for the discovery
of new drugs. However, the use of UDSC in pharmacology and toxicology tests has not been much
exploited. Since iPSCs derived from UDSC maintain the original genetic characteristics of the donor
and can differentiate in several lineages, those cells could be an added value in new drug developments
for the correction of genetic defects (Figure 2). Furthermore, due to the characteristics of USDC above
described, those cells could be a good biological model used in in vitro tests to predict toxicity in
drug discovery. Nevertheless, this is an area of very large interest, and it is likely to grow in the next
few years.
Cells 2020, 9, 573 9 of 19
4. Use of Urine-Derived Stem Cells (UDSC) for Regenerative Medicine
4.1. Urological Tissue Engineering
For urological tissue regeneration purposes, bone marrow mesenchymal stroma cells do not
efficiently differentiate into functional urothelial cells, while UDSC have a better performance [32].
UDSC differentiated into urothelial and smooth muscle cells were previously co-cultured in layers
into specific 3D porous small intestinal submucosa scaffolds. The multilayer structure obtained
was comparable to the tissue of the urinary tract, suggesting that UDSC can be used for urological
tissue regeneration [44]. The treatment of stress urinary incontinence can benefit from the ability
of UDSC to differentiate into endothelial, myogenic and neurogenic directions, as it was previously
demonstrated. In this study, UDSC mixed with alginate microbeads, containing growth factors (VEGF,
insulin-like growth factor 1, fibroblast growth factor-1, PDGF, hepatocyte growth factor and nerve
growth factor) and collagen-I, were injected subcutaneously into nude mice. The injection of UDSC
with growth factors stimulated resident cell survival, myogenesis, enhanced revascularization and
innervation, while UDSC themselves differentiated into a myogenic lineage [55]. In a follow-up
experiment, the authors modified UDSC with an adenovirus-containing human vascular endothelial
growth factor 165 (VEGF165), known to improve cell survival, angiogenesis and the myogenesis of
MSC [65]. Subcutaneous implantation of UDSC, overexpressing (VEGF165) or added to endothelial
cells/human skeletal myoblasts (as control) suspended in collagen-I-containing gel into nude mice led to
increased survival of implanted cells, efficient differentiation of cells into endothelial cells and myocytes,
stimulated vascularization and regeneration of nerve fibers [55]. Both experimental studies were a
good approach for the development of cell therapies for the correction of stress urinary incontinence.
Besides their use for stress urinary incontinence, Liu et al. investigated the usefulness of UDSC for
urethral reconstruction. Isolated rabbit UDSC were seeded on small intestine submucosa scaffolds and
transplanted to repair the urethral defect of white male rabbits. The graft, containing autologous UDSC,
facilitated urothelial regeneration and decreased inflammation and post-surgical fibrosis. Transplanted
UDSC differentiated into smooth muscle and urothelial cells, improving smooth muscle and vessels
content [51].
Although UDSC present some limitations in terms of differentiation potential, a recent study
demonstrated that, although those cells did not show chondrogenic differentiation capacity, the
decellularized matrix deposited by them provided a 3D expansion substrate to promote senescent
bone marrow stromal cells’ chondrogenic potential, which provided an additional approach for the
application of UDSC in tissue engineering and regeneration [66].
Transplantation of UDSC may be applied, not only for bladder or urethra reconstruction but also
for the preservation of the erectile function in a rat model of a cavernous nerve injury. The authors
modeled bilateral cavernous nerve injury-induced erectile dysfunction in rats and injected UDSC into
the penile cavernous bodies. UDSC were genetically modified with a pigment epithelium-derived
factor. As a result, they increased the smooth muscle to collagen ratio and decreased expression of
transforming growth factor-b1, and decreased cell apoptosis and fibrosis in the cavernous tissue were
observed. Furthermore, the paracrine effects of transplanted UDSC led to nerve protection, prevention
of erectile dysfunction and improvement of endothelial cell function [67].
4.2. Bone Regeneration
In another application, UDSC seeded onto bone tissue engineering scaffolds, such as β-tricalcium
phosphate and calcium silicate incorporated into poly(lactic-co-glycolic acid), showed increased
osteogenic differentiation and potential for bone regeneration when implanted in vivo (rat and mice).
Bone formation probably involved the Wnt/β-catenin signaling pathway activation, a mechanism
already known to be associated with bone formation [23,38]. Furthermore, silver nanoparticles, which
are recognized as an excellent antimicrobial agent for use on scaffolds, and bone morphogenic protein
2 transduction also promote the osteogenic differentiation of UDSC in vitro and also in vivo [68,69].
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Therefore, the use of UDSC to repair bone tissue injuries is clearly as promising as for genitourinary
system regeneration.
4.3. Neuroregeneration
In a neuronal context, UDSC can be reprogrammed into iPSC and differentiated into neural
progenitor cells with further in vitro induction to neurons-, oligodendrocytes- and astrocytes-like
cells. In the same work, the authors suggested a method of purification of neural progenitor cells
from undifferentiated cells using fluorescence-activated cell sorting with the A2B5 antibody. Being
transplanted into a mouse with contusion of the thoracic spinal cord-purified neural progenitor cells
survived, integrated into the injured spinal cord, and differentiated into neurons and glia without
tumor formation [51]. Additionally, when UDSC were injected directly into the rat brain, positive
neuronal markers were found after three weeks, suggesting that the brain environment can induce
neuronal differentiation of UDSC [29].
4.4. Dental Reconstruction Applications
Dental tissue was also previously obtained by differentiation of iPSC generated from UDSC [70].
iPSC were generated from human UDSC and were differentiated into epithelial sheets while placed
on the top of one mouse dental mesenchyme (E14.5). One to two days after incubation, this chimeric
culture graft was transplanted into the renal subcapsular layer of adult nude mice. Interestingly, around
30% of these transplanted sheets developed into ameloblasts in a tooth-like structure. Thus, human
iPSC, pre-differentiated into epithelial sheets, may contribute to tooth development by responding to
odontogenic signals from embryonic dental mesenchyme. These results may be useful for further drug
screening or regenerative therapies in dentistry [70].
4.5. Urine-Derived Stem Cells (UDSC) Extracellular Vesicles and Exosomes
Beyond UDSC themselves, it has been recently proposed that exosomes released from those cells
have also therapeutic activity. Chen et al. demonstrated that systemic injection of extracellular vesicles
from human-harvested UDSC prevented osteoporosis in ovariectomized mice by transferring collagen
triple-helix repeat containing 1 (CTHRC1) and osteoprotegerin (OPG) [71]. The same strategy was
done to improve erectile dysfunction in a diabetic rat model—this time, by means of transferring
pro-angiogenic miRNA [72]—and to decrease kidney injury in a diabetic rat model by transferring
pro-vascular regeneration and cell protection factors, including growth factor, transforming growth
factor-β1, angiogenin and bone morphogenetic protein-7 [73]. In the same disease context, Jin et al.
demonstrated that exosomes from UDSC attenuated podocyte apoptosis in a mouse model of diabetes,
besides decreasing apoptosis and increasing autophagy fluxes when added to MPC5 cells exposed
to hyperglycemia. The molecular mechanism proposed was through increasing the expression of
miR-486 [74].
UDSC-derived extracellular vesicles (EVs) may also play an indirect role towards the immune
system. Recently, an immunomodulatory effect of EVs from MSCs has been raised mainly due to
its endocrine/paracrine effects on damaged tissues. EVs can transfer proteins, lipids, mRNAs, and
long noncoding RNAs between various cell types, thus mediating intercellular communication and
signaling. Indeed, depending on its origin, EVs may aggravate or promote injury, as in cancer, or
they are capable of modulating immune cells [75–77]. To highlight this phenomenon, in a rat renal
injury model, MSC-EVs were able to reduce IL1-B and TNF-alpha [76,78]. The expression of IL-10, an
important anti-inflammatory cytokine, was also shown to be regulated by EVs [79]. Other authors have
suggested that MSC-EVs are able to control renal macrophage infiltration [80]. The precise mechanism
by which EVs regulate the immune system is still unknown. One of the possible mechanisms is
through microRNAs. For example, both miRs 21 and 199a, or miR-15a, are described to play an
immunomodulatory role or even modulate macrophages chemoattraction [81–83]. Although this has
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not been established yet, it is reasonable to think that UDSCs could also have an immunomodulatory
role. Nevertheless, to establish this new capacity, more comprehensive research needs to be performed.
In conclusion, UDSC or their derived EVs can potentially be used in cell therapy for a variety
of conditions, although more studies are needed, as well as their clinical translation discussed. Of
interest is the fact that exosomes released by UDSC appear to carry biologically active molecules, with
meaningful and relevant therapeutic impacts.
5. Potential or Current Utilization of Urine-Derived Stem Cells as Disease Models
For the study of disease staging and drug development assays, animal models have the drawback
of not always accurately mimicking the precise human gene expression and physiology, which limits
extrapolating results from animal models to humans. Although human cells are certainly a good
option for disease modeling, their collection is often invasive and poses ethical problems. Cell-based
technologies are an opportunity to model various human diseases in a culture dish. For such purposes,
differentiated cells are needed; however, their isolation and long-term cultures are still a limiting step.
In this case, the use of iPSC may be a good alternative, although the approach requires characterization,
including the reprogramming and in vitro differentiation processes [84]. A great advantage of iPSC is
the ability of human disease-specific iPSC to present the genetic background of a targeted disease [85–87].
UDSC can be successfully reprogrammed into iPSC, and their ability of differentiation into multiple
fates can generate models for different conditions: metabolic, autoimmune and hemorrhagic disorders
and diseases of cardiovascular, nervous, muscular or urinary systems, among many others. One such
example is hemophilia A, from which iPSC were previously generated from human UDSC, which were
further differentiated into hepatocytes that did not produce blood coagulation factor VIII, resembling
patient cells [88]. Since the isolation of UDSC is noninvasive, they are a safe and promising source
of stem cells from patients with bleeding disorders, since all invasive procedures are life-threatening
for them [89]. The CRISPR-Cas9 nuclease system was successfully used by Park et al. on iPSC from
patients with hemophilia A caused by chromosomal inversions that involve introns 1 and 22 of the F8
(blood coagulation factor VIII) gene [90]. The CRISPR-Cas9 technology was used in iPSCs in order to
revert chromosomal segments to the appropriate position, being later differentiated into endothelial
cells. These endothelial cells expressed the F8 gene and functionally rescued factor VIII deficiency in a
mouse model of hemophilia.
Another example of iPSC application regards fibrodysplasia ossificans progressiva (FOP), a
genetic disease caused by a heterozygous missense mutation in the activin receptor-like kinase 2 gene
(ACVR1/ALK2) and characterized by progressive heterotopic ossification of soft tissues [91]. iPSC
generated from urine cells from patients with fibrodysplasia ossificans progressiva showed ALK2
mutations that led to a decreased ability of cells to differentiate into bone and appeared to have reduced
expression of the VEGF receptor 2 in differentiated endothelial cells. This cell line can be applied
as an alternative research model to evaluate ALK2 bioactivity and therapeutic drugs to inhibit the
mineralization of soft tissues [92].
It has been previously observed that iPSC derived from human UDSC can differentiate into
human alveolar type II (AT II) epithelial cells, which are responsible for the production of surfactants.
Differentiated cells showed outstretched and epithelium-like morphology and expressed surfactant
proteins A, B and C-like mature human AT II cells, modeling lung disease caused by the dysfunction
of AT II cells [93].
The same approach was also used to obtain iPSC from UDSC of patients with Down syndrome.
These T21-iPSC differentiated into glutamatergic neurons that had the ability to fire action potentials
and into cardiomyocytes that had spontaneous contractions and were sensitive to the β-adrenergic
agonist isoproterenol [53].
The identification of cardiac dysfunction in patients with specific genetic backgrounds is
problematic, since a source of human cardiomyocytes is limited. Facing this, Jouni et al. generated
iPSC from UDSC of patients with a rare genetically-inherited cardiac disease, the long QT syndrome.
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Differentiation of the generated iPSC into functional cardiomyocytes allowed to define trafficking
defects, which led to a delayed rectifier potassium current and prolonged action potential. In patients,
such changes can lead to potentially fatal cardiac arrhythmias [49].
UDSC from healthy individuals and muscular dystrophy patients can also be directly
reprogrammed, by transduction with a tamoxifen-inducible MyoD lentiviral vector into functional
myogenic cells, which express transcripts for muscle markers, form sarcomeres and have the capacity
of contraction while harboring the mutation [94]. Furthermore, CRISPR/Cas9-edited USC produced
the most frequent mutation responsible for limb-girdle muscular dystrophy type 2C [94]. Additionally,
the antisense oligonucleotide strategy was used to correct the defect of dystrophin exon 44, by exon
skipping, in UDSC differentiated into myogenic cells from Duchenne muscular dystrophy patients and
healthy controls [95].
iPSCs were also used to generate cardiomyocytes from patients with cryptorchid-specific iPSC lines
with genetic variations [96], hepatocyte-like cells with mutated proprotein convertase subtilisin/kexin
type 9 to mimic the pathophysiology of autosomal dominant hypercholesterolemia [97] and systemic
lupus erythematosus-specific iPSC from UDSC [54].
6. Advantages and Challenges of Urine-Derived Stem Cells (UDSC)
As described above, urine collection preceding UDSC isolation is easy, safe, noninvasive and
inexpensive, unlike surgical biopsies associated with the collection of other stem cell types. UDSC can
be isolated from healthy and unhealthy individuals while maintaining proliferation and differentiation
capacity, allowing the possibility of large-scale noninvasive sample collection and storage. Furthermore,
no major ethical concerns are applied to UDSC collection, and they can be used for personalized and
high-throughput research or clinical applications, such as in vitro pharmacological tests, regenerative
medicine and as a disease model.
Regarding challenges and open questions, UDSC biological characterizations need to be deeper
explored, with a special focus on donor age effects on UDSC properties, as previously mentioned.
Moreover, in UDSC, the expression levels of some characteristic surface markers, analyzed by flow
cytometry, show discrepancy among different studies [20,21,29,32,38,46,68,69,73,84,95,98–100]. These
discrepancies can be attributed to different culture conditions, such as the composition of the culture
medium, or can be a native characteristic of the isolated cells that can be heterogeneous within the
same individual or between different individuals. Further studies to gather relevant information about
expression levels of surface markers and their significance for UDSC biology are important.
Conceivably, autologous UDSC can be used to mitigate age-related conditions, provided that cells
are collected at a younger age and cryo-preserved. Nonetheless, the maintenance of UDSC features
when isolated from old individuals is not adequately assessed and is a crucial question to unveil. Gao
et al. compared UDSC isolated from different age groups (5 to 14 years old, 30 to 40 years old and 65
to 75 years old), showing that, although the older group can still proliferate and undergo osteogenic
differentiation, these properties decrease with age, and the count of senescent cells increases [46].
The maintenance of UDSC properties after cryopreservation would be beneficial for some
experimental designs. However, to our knowledge, this process was not well-described. Consequently,
along with the impact of donor age on the properties of isolated UDSC, the origin of UDSC, urine
preservation methods for subsequent UDSC isolation and cryopreservation methods maintaining
UDSC properties needs to be explored. Considering that there is a negative impact of aging on UDSC
biology, the discovery of approaches to improve the properties of UDSC from elder individuals has
considerable relevance before clinical applications.
As reviewed by Ji et al. [84], human individuals have a diverse genetic background, thereby
increasing the variability of obtained results and making data explanation difficult. To overcome this
issue, it would be beneficial to enlarge the population sample or establish the control and experimental
group from the same cell source with the matching genetic background. The second possibility implies
that the experimental group is created by targeted genome editing. It has been reported that iPSC
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can retain epigenetic transcriptional memory from the donor, and these traits change according to the
original cell type and can influence iPSC properties such as differentiation potential with a bias towards
the cell type of origin [101]. These can affect the future applications of UDSC. Concerning clinical
applications, UDSC and derived cells’ safety and effectiveness conditions to be used are not established.
For example, iPSC complete differentiation must be achieved before clinical transplantation, since iPSC
can form teratomas when implanted.
Although numerous interesting studies have already been performed and, clearly, iPSC generated
from UDSC are a promising cell source for various laboratory, fundamental and clinical applications,
there are still a lot of important points to clarify, and several steps of the procedures need to be
standardized. One involves the optimization and standardization of the urine samples collection
method. There are various methods, including the collection of voided urine, catheterization or the
collection of upper urinary tract urine. The protocol for collection can determine the type of isolated
cells and their growth and proliferation potential. A variety of methods brings the diversity of isolated
cells, differentiation capabilities, theories concerning the origin of UDSC and the multiplicity of results
interpretations. Additionally, strict eligibility requirements for UDSC donors should be established,
while all the procedures should be carried out in an ethical way and under quality control. In the same
context, a rapid method for the detection of urine samples’ contamination is required [102].
7. Conclusions
UDCs’ impact on personalized and regenerative medicine has been increasing, despite the
still-open questions. One advantage related to other sources of human biological material is the
noninvasive nature of their collection, which simplifies ethical concerns. When searching Pubmed
with the keywords “urine-derived cells”, we obtain a total of three publications in 2010 and 52 in 2019.
It is very likely that the number will steadily increase as more is discovered about this very particular
group of cells. The next years will tell whether UDC will be a critical tool in biomedicine.
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